Vitestro has raised $70m to advance development and broaden the commercialisation of its autonomous blood-drawing robot.
The Dutch company’s oversubscribed Series B financing round saw a mix of strategic and financial investment from new participants including Mayo Clinic, Sutter Health, Puma Venture Capital, and ROM Ultrecht. Existing investors including NYBC Ventures and Sonder Capital also participated.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Vitestro’s Aletta Autonomous Robotic Phlebotomy Device (ARPD) is a robotic system for autonomous diagnostic blood collection. Combining multimodal imaging and artificial intelligence (AI), the venepuncture system is designed to alleviate staffing pressures and improve patient experience in clinical settings.
ARPD obtained a European CE mark in August 2024, becoming the first robotic system of its kind to receive this designation. Vitestro began deploying the system in a limited range of healthcare settings across Europe in March 2025.
Vitestro said the latest funds will support ARPD’s US regulatory clearance via the US Food and Drug Administration’s (FDA) de novo pathway and advance global commercial edicts such as manufacturing scale and infrastructural development.
Vitestro’s ADOPT pivotal trial (NCT05878483) of ARPD completed in July 2025, as per the study’s entry on Clinicaltrials.gov. While full results of this study have not yet been released, interim data released in May 2024 revealed that ARPD met its primary endpoint by achieving 95% first-stick success, comparable to manual venipuncture first-stick success rates of 93-97%, as per the company. First-stick success refers to the clinical achievement of successfully performing a blood draw on the first attempt.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOn the developmental front, Vitestro added that the latest funding will be used to advance ARPD’s technical capabilities and integration into existing technology infrastructure.
Vitestro’s CEO, Toon Overbeeke said: “Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection.
“Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption.”
In the healthcare space, robotic systems are predominantly used in surgical procedures. According to GlobalData analysis, the robotic surgery market is growing at a CAGR of 5.6% and is projected to reach a valuation of around $17.3bn in 2035. However, Vitestro’s fundraise reflects investor confidence in the use of robotics in further clinical workflows.
